ImmunoGen Inc (NASDAQ:IMGN)

10.27
Delayed Data
As of Apr 20
 +0.03 / +0.29%
Today’s Change
3.59
Today|||52-Week Range
13.41
+60.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. Its product candidates include Mirvetuximab Soravtansine, Coltuximab ravtansine, and Kadcyla . The company was founded in March 1981 and is headquartered in Waltham, MA.

Contact Information

ImmunoGen, Inc.
830 Winter Street
Waltham Massachusetts 02451-1477
P:(781) 895-0600
Investor Relations:

Employees

Shareholders

Other institutional44.85%
Mutual fund holders34.56%
Individual stakeholders2.05%

Top Executives

Mark J. EnyedyPresident, Chief Executive Officer & Director
David B. JohnstonChief Financial Officer & Executive Vice President
Richard J. GregoryChief Scientific Officer & Executive VP
Anna BerkenblitChief Medical Officer & Vice President
Craig BarrowsSecretary, Vice President & General Counsel